Stock listing
603035 Stock Price, News, Filings & Events — Acadia Pharmaceuticals Inc.
Selected listing: 603035 · LS · EUR · DE
This page tracks Acadia Pharmaceuticals Inc.'s 603035:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 603035:LS. 603035:LS is the stock-level entry point for investors researching Acadia Pharmaceuticals Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Acadia Pharmaceuticals Inc. (ticker: ACAD) is a publicly traded company based in the United States, with a market capitalization of approximately $4.25 billion. The company focuses on developing innovative therapies for central nervous system disorders. Acadia is committed to advancing its pipeline to address unmet medical needs in this area.
- Ticker
- 603035:LS
- Asset type
- Stock
- Market cap
- $5.02B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Acadia Pharmaceuticals Inc. 603035:LS stock context
This page tracks Acadia Pharmaceuticals Inc.'s 603035:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 603035:LS. 603035:LS is the stock-level entry point for investors researching Acadia Pharmaceuticals Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Acadia Pharmaceuticals Inc. (ticker: ACAD) is a publicly traded company based in the United States, with a market capitalization of approximately $4.25 billion. The company focuses on developing innovative therapies for central nervous system disorders. Acadia is committed to advancing its pipeline to address unmet medical needs in this area.
Latest news from Acadia Pharmaceuticals Inc.
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the Eu...
August 24, 2026
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 30, 2026
Acadian Asset Management : Reports Financial and Operating Results for the Second Quarter Ended June 30, 2026 (Presentation)
July 30, 2026
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
July 20, 2026
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
July 15, 2026
Acadia Pharmaceuticals Inc. earnings calls
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call
August 4, 2026 · Replay with transcript and chapters
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call
May 6, 2026 · Replay with transcript and chapters
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call
February 25, 2026 · Replay with transcript and chapters
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call
November 5, 2025 · Replay with transcript and chapters
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call
August 6, 2025 · Replay with transcript and chapters
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Call
May 7, 2025 · Replay with transcript and chapters
Research Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. investor report
Review AI stock analysis and investor report context for 603035:LS.
Acadia Pharmaceuticals Inc. company profile
View the public company page for Acadia Pharmaceuticals Inc. on 6ix.
Acadia Pharmaceuticals Inc. news
Read company news and market updates connected to Acadia Pharmaceuticals Inc..
Acadia Pharmaceuticals Inc. investor events
Find investor webinars, events, and replay context for Acadia Pharmaceuticals Inc..
Alternate listings
ACAD:NASDAQ
US · USD
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
DR6:GETTEX
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
DR6:TRADEGATE
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
ACAD:BMV
MX · MXN
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
603035:LSX
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
DR6:FWB
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
ACAD:BIVA
MX · MXN
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
ACAD:BOATS
US · USD
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
0A4W:LSE
GB · USD
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
DR6:DUS
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
DR6:MUN
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.
DR6:SWB
DE · EUR
Alternate listing for Acadia Pharmaceuticals Inc.; the primary context on this page is 603035:LS.